Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An effectiveness study of the combination of dapagliflozin and liraglutide in NAFLD patients with T2DM compared with dapagliflozin, liraglutide, sitagliptin, and pioglitazone

Trial Profile

An effectiveness study of the combination of dapagliflozin and liraglutide in NAFLD patients with T2DM compared with dapagliflozin, liraglutide, sitagliptin, and pioglitazone

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Oct 2018

At a glance

  • Drugs Dapagliflozin (Primary) ; Liraglutide (Primary) ; Metformin; Pioglitazone; Sitagliptin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 18 Oct 2018 New trial record
    • 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top